Oruka Therapeutics posted Phase 2 results for ORKA-001 in plaque psoriasis, reporting that 63% of patients achieved complete skin clearance at 16 weeks and that updated exposure data supports once-yearly injection potential. The company also reported 83% achieving PASI 90 and said tolerability aligned with other IL-23 inhibitors. Analysts framed the data as a strong competitive signal versus marketed and late-stage IL-23 therapies, although Oruka still needs late-stage trials to establish durability, safety, and real-world remission duration. Oruka’s design aims to match efficacy while reducing injection frequency, targeting a differentiation strategy around convenience and adherence. The company said blood exposure analyses support the longer dosing interval, which could be central to its differentiation if confirmed in later studies. The readout increases pressure on incumbents in psoriasis pharmacology and underscores continuing investment into next-generation IL-23 orals/long-interval formulations.